Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia

Part of paid clinical trials in Houston, Texas.

Sponsor
Bristol-Myers Squibb
Study ID
NCT00732186
Phase
PHASE1
Status
Withdrawn

Conditions

  • Leukemia, Myeloid, Chronic

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ipilimumab — BIOLOGICAL
    IV Solution, IV, 10 mg/kg, (if dose reduction necessary at 3 mg/kg), Every three weeks for the first 10 weeks, with a booster at week 22, Up to 38 weeks depending on response

Study Details

The purpose of the study is to assess the safety of ipilimumab and dasatinib combination therapy in patients with CML

Key Dates

Start date
Aug 31, 2009
Status verified
Nov 2009
Primary completion
Feb 28, 2011
Completion
Feb 28, 2011

Study Design

Enrollment
0 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Group 1 and Group 2

Primary Outcome Measure

To evaluate the safety of ipilimumab in combination with dasatinib in CML patients with a loss of previously achieved major molecular response or a loss of previously achieved cytogenetic response to dasatinib [ Time Frame: At weeks 1, 4, 7, 10, 14, 18, 22, 26, 30, 34 and 38 ]

Locations (1)

FacilityCityStateZIPSite coordinators
The University Of Texas, M.D. Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By research site
The University Of Texas, M.D. Anderson Cancer Center· Houston, TX

Related Studies